|
GMT+8 |
3 JUNE （FRI） |
|
14:00-15:30 |
Postgraduate course - Portal hypertension |
|
14:00-14:20 |
Introduction of portal hypertension: definition and classification Juan Carlos Garcia - PAGAN, Barcelona |
|
14:20-14:40 |
Cirrhotic portal hypertension: evaluation and staging Mattias MANDORFER, Vienna |
|
14:40-15:00 |
Non-cirrhotic portal hypertension: diagnostic approach Ashish KUMAR, New Delhi |
|
15:00-15:20 |
Rare causes of portal hypertension: hematological and vascular causes Jiyao WANG, Shanghai |
|
15:20-15:30 |
Discussion |
|
15:30-17:00 |
Postgraduate course - Portal hypertension and decompensation |
|
15:30-15:50 |
Prophylaxis of variceal hemorrhage in patients with cirrhosis: Endoscopic Approach Shutian ZHANG, Beijing |
|
15:50-16:10 |
Management of ascites in decompensated cirrhosis Paolo ANGELI, Padova |
|
16:10-16:30 |
New concept and management of acute kidney injury Samuel S. LEE, Palo Alto, CA |
|
16:30-16:50 |
Targeting and immunotherapy of HCC in cirrhotic patients Kwang-Hyub HAN, Seoul |
|
16:50-17:00 |
Discussion |
|
GMT+8 |
3 JUNE （FRI） |
|
18:00-20:00 |
State-of-the-art 1 |
|
18:00-18:30 |
Mechanisms of portal hypertension and regression Jordi Gracia-SANCHO, Barcelona |
|
18:30-19:00 |
Therapies of portal hypertension and regression Weifen XIE, Beijing |
|
19:00-20:00 |
Consensus on regression of portal hypertension Jordi Gracia-SANCHO, Barcelona
|
|
GMT+8 |
4 JUNE （SAT） |
|
09:00-10:00 |
State-of-the-art 2 |
|
09:00-09:30 |
Mechanisms of fibrosis resolution and liver regeneration David BRENNER, San Diego |
|
09:30-10:00 |
Cirrhotic portal hypertension: evaluation and staging Guadalupe Garcia-TSAO, New Heaven |
|
18:00-19:00 |
State-of-the-art 3 |
|
18:00-18:30 |
Non-invasive assessment of clinically significant portal hypertension Shiv K. SARIN, New Delhi |
|
18:30-19:00 |
Non-invasive assessment of liver fibrosis- From research to clinical practice Laurent CASTERA, Clichy |
|
GMT+8 |
5 JUNE （SUN） |
|
09:00-10:00 |
State-of-the-art 4 |
|
09:00-09:30 |
Clinical trials related to liver fibrosis: What have we learnt from the past Anna S.F. LOK, Ann Arbor, MI |
|
09:30-10:00 |
Clinical implications of experimental research: What we can do in future Scott FRIEDMAN, New York |
|
18:00-19:00 |
State-of-the-art 5 |
|
18:00-18:30 |
Molecular and cellular perspectives of liver fibrosis: Future therapy Detlef SCHUPPAN, Mainz |
|
18:30-19:00 |
Endpoint choice for clinical trials in CHB George LAU, Hong Kong SAR |
|
GMT+8 |
4 JUNE （SAT） |
5 JUNE （SUN） |
|
10:00-11:30 |
Session 1. Histological diagnosis and staging of liver fibrosis |
Session 5. Etiological management - Viral hepatitis |
|
10:00-10:20 |
Histological assessment of fibrosis and cirrhosis: revised Laennec staging system Ian R. WANLESS, Halifax |
Novel targets for HBV treatment Wenhui LI, Beijing |
|
10:20-10:40 |
Viral hepatitis: biopsy grading, staging and beyond Neil D. THEISE, New York |
Clinical trials aimed at HBV cure: present and future Calvin Q Pan , New York |
|
10:40-11:00 |
NAFLD: Histopathologic feature and staging David E KLEINER, Bethesda, MD |
HCC risk prediction model for HBV patients on antiviral therapy Hwai-I YANG, Taipei |
|
11:00-11:20 |
Fully histological quantification/AI of fibrosis in clinical trial Aileen WEE, Singapore |
Treatment of fibrosis: benefits beyond HCV cure Lai WEI, Beijing |
|
11:20-11:30 |
Discussion |
Discussion |
|
11:30-13:00 |
Session 2. Non-invasive assessment - Serum biomarkers |
Session 6. Etiological management - Metabolic associated fatty liver disease |
|
11:30-11:50 |
Conventional biomarkers for liver fibrosis in clinical practice: present and future Grace L. H. WONG, Hong Kong SAR |
From NAFLD to MAFLD Tawesak TANWANDEE, Bangkok |
|
11:50-12:10 |
Markers directly related to fibrogenesis and fibrolysis |
Lean NASH and liver fibrosis |
|
12:10-12:30 |
Novel biomarkers and matrisome of liver fibrosis Wei CHEN, Beijing |
Lifestyle modification of MAFLD patients |
|
12:30-12:50 |
Can serum markers be used for as a surrogate endpoint for clinical trial Hong YOU, Beijing |
Treatment targets for Nonalcoholic Steatohepatitis |
|
12:50-13:00 |
Discussion |
Discussion |
|
13:00-14:00 |
Satellite Symposium / Free Paper |
Satellite Symposium / Free Paper |
|
14:00-15:30 |
Session 3. Imaging technology |
Session 7 Etiological management - Autoimmune and DILI |
|
14:00-14:20 |
Transient elastography (TE) for advanced chronic liver disease Seung Up KIM, Seoul |
Updates management of drug-induced liver injury: 2021 APASL guidelines Yimin MAO, Shanghai |
|
14:20-14:40 |
MRI and MRE assessment for chronic liver disease Zhenghan YANG, San Diego |
Primary Biliary Cholangitis: 2021 Practice Guidance Update from APASL Atsushi TANAKA , Tokyo |
|
14:40-15:00 |
Hepatic venous pressure gradient (HVPG) for clinical practice Guohong HAN, Xi’an |
New advances in autoimmune hepatitis Xiong MA, Shanghai |
|
15:00-15:20 |
Radiomics signature for assessment in portal hypertension Xiaolong QI, Lanzhou |
New advances in PSC and IgG4 related cholangitis Ying HAN, Xi’an |
|
15:20-15:30 |
Discussion |
Discussion |
|
15:30-17:00 |
Session 4. Traditional medicine in liver fibrosis |
Session 8 Research and trials: Novel pharmaceutical targets |
|
15:30-15:50 |
Mechanism of traditional Chinese medicine to treat liver fibrosis Chenghai LIU, Shanghai |
New targets for liver fibrosis Don C Rockey, Charleston, SC |
|
15:50-16:10 |
Evidence of TCM for HBV related fibrosis and cirrhosis |
New design for liver fibrosis |
|
16:10-16:30 |
Methodological consideration for traditional medicine research Jianping LIU, Beijing |
Role of liver fibrosis assessment in HCC risk prediction for chronic hepatitis B |
|
16:30-16:50 |
Clinical care and research of liver disease: impact of COVID19 epidemics Wenhong ZHANG, Shanghai |
New treatment for portal hypertension |
|
16:50-17:00 |
Discussion |
Discussion |
|
17:00-18:00 |
Satellite Symposium / Free Paper |
Satellite Symposium / Free Paper |